Who is sponsoring NCT01892020?

NCT01892020 is sponsored by Novo Nordisk A/S.

What condition does NCT01892020 study?

NCT01892020 studies Diabetes, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT01892020?

Interventions: biphasic insulin aspart 50, biphasic human insulin 50.

What is the status of NCT01892020?

NCT01892020 is currently COMPLETED.

Last reviewed 2015-06-16 · How we verify

A Multi-centre, Randomised, Open-labelled, 2-sequence, 2-period Crossover Trial to Investigate the Efficacy and Safety of Biphasic Insulin Aspart 50 (BIAsp 50) Twice Daily Versus Biphasic Human Insulin 50 (BHI 50) Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

NCT01892020 Phase 4 COMPLETED Results posted

This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50 (BHI 50) twice daily, both in combination with metformin, in Chinese subjects with type 2 diabetes mellitus.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 4
Status	COMPLETED
Enrolment	161
Start date	2013-06
Completion	2014-05

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 50
biphasic human insulin 50

Primary outcomes

2-hour PPG (Postprandial Plasma Glucose) Increment Following a Standard Meal Test — After 4 weeks of treatment in each treatment sequence
The 2-hour PPG increment is the difference between the plasma glucose (PG) value at 120 minutes after standard meal test and the fasting PG value.

Countries

China